Vertex says telaprevir may cut down HCV treatment time

08/11/2010 | Google

Some hepatitis C patients who took drug candidate telaprevir were able to finish treatment sooner than with standard therapy, according to Vertex Pharmaceuticals. The company said patients in the clinical trial who responded quickly to telaprevir had better results after 24 weeks of therapy compared with 48 weeks.

View Full Article in:

Google

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT